|
 Aveo, which cut 62 percent of its workforce last
year to focus on developing the drug, tivozanib, as a treatment for
breast and colon cancers, said in December that the drug was not
likely to succeed in a mid-stage trial testing its use in colon
cancer.
The companies said on Friday they would discontinue the study.
A mid-stage trial testing tivozanib as a treatment for breast cancer
was stopped last month due to insufficient enrolments.
Tivozanib was rejected by U.S. health regulators in June for use in
kidney cancer, citing inconsistent study results.
The termination of the collaboration will be effective August 11,
after which Aveo will retain the rights to the drug, the companies
said in a statement.
The two companies had signed a worldwide agreement to develop and
market tivozanib outside of Asia for the treatment of a broad range
of cancers in February 2011.
[to top of second column] |
Cambridge, Massachusetts-based Aveo's shares have lost nearly 7
percent of their value since December 13, when the company said the
drug was unlikely to succeed as a treatment for colon cancer. The
stock closed at $1.75 on the Nasdaq on Thursday.
(Reporting by Natalie Grover in
Bangalore; editing by Savio D'Souza, Maju Samuel)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
